Vertex mulls sale of hepatitis C drug to focus on cystic fibrosis
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals is considering selling its next -generation hepatitis C drug to focus on its cystic fibrosis treatment program, CEO Jeffrey Leiden told Scrip.